Background: Intergenotypic recombinant hepatitis C virus (HCV) strains emerge rarely during coinfection of the same individual with two HCV genotypes. Few recombinant HCV strains have been identified to date and only one, CRF01 2k/1b, has become a worldwide concern. This study reevaluated the genotyping of three HCV genotype 2 strains from a group of patients with an unusually low rate of sustained virological response after pegylated interferon/ribavirin treatment. In addition, genetic determinants of host interferon resistance were evaluated.
Methods: The HCV type 2 strains from the patients' serum were subjected to partial sequencing of the core-E1, NS2, NS5A and NS5B regions by reverse transcription polymerase chain reaction. Furthermore, the IFNL3 rs12979860 and the IFNL4 rs368234815 single nucleotide polymorphisms were defined in two of the three patients.
Results: All three strains were phylogenetically related to the Russia-derived CRF01 2k/1b while they encompassed the exact same 2k/1b junction site within NS2.
Conclusion: This is the first report of HCV 2k/1b recombinants in Greece and the greater area of the Balkans.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302191 | PMC |
| http://dx.doi.org/10.20524/aog.2018.0322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of immune checkpoint inhibitors on patients with hepatitis B virus infection.
J Chin Med Assoc
December 2024
Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Hepatitis B virus (HBV) infection is regarded as a major health concern worldwide. In patients with chronic HBV infection, exhausted virus-specific CD8+ T cells, resulting from the activation of the programmed cell death protein 1 and programmed death ligand 1 axis, play a key role in the chronicity of infection. Functional cure for HBV, defined as the seroclearance of hepatitis B surface antigen (HBsAg), is viewed as the optimal goal of chronic HBV infection treatment because HBsAg loss is associated with a low risk of hepatocellular carcinoma and a relatively favorable prognosis.
View Article and Find Full Text PDFReply to: "ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B patients with Peg-IFNα based therapy".
J Hepatol
December 2024
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR. Electronic address:
Adherence to recommended blood-based screening tests for cancer and chronic diseases: A systematic literature review.
Prev Med
December 2024
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Introduction: Blood-based tests represent a compelling option for early detection and management of cancers and other chronic diseases. While they may increase patient engagement, assumptions about greater adherence in clinical practice need further evaluation. This systematic review aimed to evaluate real-world adherence to established blood-based tests for commonly recommended screening indications to inform expectations for average-risk colorectal cancer (CRC) screening.
View Article and Find Full Text PDFLetter to the Editor: Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
Hepatology
December 2024
Department of Clinical Pharmacy, Xiangtan Central Hospital（The affiliated hospital of Hunan university), Xiangtan 411100, China.
Editorial: PIVKA-II Facilitates Risk Stratification for HCC Following HCV Cure-Authors' Reply.
Aliment Pharmacol Ther
December 2024
Department of Medical Sciences, Liver Unit, University of Turin, Turin, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!